ClinicalTrials.gg
Drug

Rosiglitazone-metformin combination clinical trials

studies test it
5
open now
0
in phase 3
3
first study started
2004

How each study uses rosiglitazone-metformin combination is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
10 Oct 2002 · AVANDAMET · NDA 021410 (FDA, Drugs@FDA)
European Union
20 Oct 2003 · Avandamet · EMEA/H/C/000522 (EMA; now expired)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Avandamet
4

Studies by the year they started

5 studies that test it; most in 2004 (2)

Studies that test rosiglitazone-metformin combination, by start year
YearStudies
20042
20051
20062

By phase

A phase 1/2 study counts in both.

Phase 3
3
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 2 · Other 3

GlaxoSmithKline (2) · Canadian Heart Research Centre (1) · Samuel Lunenfeld Research Institute, Mount Sinai Hospital (1) · Intermountain Health Care, Inc. (1)

Often tested with

Tested in the same studies.

Metformin (2) · Rosiglitazone (1) · Glimepiride (1)

Studies

Open first, then newest update. How each study uses rosiglitazone-metformin combination is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5

Given beside what is tested · 1 — rosiglitazone-metformin combination is usual care or a partner of the new treatment